Program
cliramitug
Also written as “ALXN2220” and “NI006”.
Its studies are mostly in Amyloidosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 33 open or running | phase 3since Nov 15, 2023 | Nov 15, 2023 | Dec 6, 2027phase 3 · NCT06183931 |
| Neurimmune | 21 open or running | phase 2since Sep 15, 2025 | Mar 11, 2020 | none ahead |
- Named in AstraZeneca’s own pipeline as
cliramitug
, phase 3, as of Oct 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2020First study: phase 1 study in AmyloidosisNew to NeurimmuneNeurimmune · NCT04360434 · 46 enrolled · France, Germany, Netherlands and more
- Nov 15, 2023AstraZeneca's first study: phase 3 study in AmyloidosisNew to AstraZenecaAstraZeneca · NCT06183931 · 1,182 enrolled · United States, Argentina, Australia and more
- Sep 15, 2025Phase 2 study in AmyloidosisNeurimmune · NCT07213583 · 35 enrolled · France, Germany, Netherlands and more
- May 12, 2026Phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07608354 · 326 enrolled · United States, Canada, China and more
- Aug 18, 2026Phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07789483 · 1,180 planned · United States, Argentina, Australia and more
Ahead
- Dec 6, 2027Primary completion: phase 3 study in AmyloidosisAstraZeneca · NCT06183931
- Feb 6, 2029Primary completion: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07608354
- Jul 11, 2030Primary completion: phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)AstraZeneca · NCT07789483
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · United States, Argentina, Australia and more | 3 | Not yet recruiting | AstraZeneca | Jul 11, 2030 | 1,180 |
| NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · United States, Canada, China and more | 2 | Active, not recruiting | AstraZeneca | Feb 6, 2029 | 326 |
| NCT07213583Amyloidosis · France, Germany, Netherlands and more | 2 | Active, not recruiting | Neurimmune | Oct 31, 2026 | 35 |
| NCT06183931Amyloidosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Dec 6, 2027 | 1,182 |
| NCT04360434Amyloidosis · France, Germany, Netherlands and more | 1 | Completed | Neurimmune | Jul 26, 2023 | 46 |
How it is read
Names in the registry
- “ALXN2220”, 4 entries
- “NI006”, 1 entry
Conditions, from the studies’ own filings
- Amyloidosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.